

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## CSPC PHARMACEUTICAL GROUP LIMITED

### 石藥集團有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 1093)**

### VOLUNTARY ANNOUNCEMENT

#### INVESTIGATIONAL NEW DRUG “ALMB-0166” OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that AlaMab Therapeutics (Shanghai) Inc.\* (上海恩樂邁生物科技有限公司), a subsidiary of the Company, has obtained approval from the National Medical Products Administration of the People’s Republic of China for conducting clinical trial of the investigational new drug ALMB-0166 for the treatment of acute spinal cord injury in China.

ALMB-0166 is a first-in-class humanized monoclonal antibody antagonist for novel target hemichannel connexin 43 membrane protein, which is independently developed by AlaMab Therapeutics Inc. (“**AlaMab**”), a subsidiary of the Company, for the treatment of acute spinal cord injury, stroke, osteoarthritis and other serious neurological diseases. ALMB-0166 has been granted orphan-drug designation by the U.S. FDA in 2018 for the treatment of acute spinal cord injury, and dosing in a Phase I clinical trial for the same indication in Australia has been completed with excellent safety and tolerability revealed.

AlaMab is an innovative biopharmaceutical company in the U.S. dedicated to the research and development of first-in-class antibody drugs. ALMB-0168, another product of AlaMab for the same target but with different mechanism, is currently in Phase I clinical trial for the treatment of bone cancer and bone metastases. AlaMab is making unremitting efforts to expedite the research and development progress of these two drug candidates.

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**Cai Dongchen**  
*Chairman*

Hong Kong, 1 December 2020

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. PAN Weidong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.*

\* *For identification purpose only*